# Decreased time on mechanical ventilation when comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial.

Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
	☐ Protocol		
Overall study status	Statistical analysis plan		
Completed	[X] Results		
<b>Condition category</b> Surgery	[] Individual participant data		
	No longer recruiting  Overall study status  Completed  Condition category		

# **Plain English summary of protocol**Not provided at time of registration

### Contact information

# Type(s)

Scientific

### Contact name

Dr Andrew Kirkham

### Contact details

GlaxoSmithKline Greenford Road Greenford, Middlesex United Kingdom UB6 OHE

## Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

### Secondary identifying numbers

USA30226

# Study information

### Scientific Title

### Study objectives

Not provided at time of registration

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

### Health condition(s) or problem(s) studied

Medical or surgical patients requiring intensive care.

### Interventions

Comparing analgesia-based sedation using remifentanil versus standard hypnotic-based sedation for up to 10 days in intensive care unit patients. Titration of analgesia/sedation to achieve optimal sedation. Regular assessments of haemodynamics.

### Intervention Type

Drug

### Phase

**Not Specified** 

### Drug/device/biological/vaccine name(s)

Remifentanil

### Primary outcome measure

Not provided at time of registration

### Secondary outcome measures

Not provided at time of registration

### Overall study start date

07/06/2002

### Completion date

30/06/2003

# **Eligibility**

### Key inclusion criteria

Critically ill patients requiring 3-10 days of mechanical ventilation.

### Participant type(s)

**Patient** 

### Age group

**Not Specified** 

### Sex

**Not Specified** 

### Target number of participants

Not provided at time of registration

### Key exclusion criteria

Not provided at time of registration

### Date of first enrolment

07/06/2002

### Date of final enrolment

30/06/2003

### Locations

### Countries of recruitment

Austria

Belgium

Denmark

France

Netherlands

Portugal

United Arab Emirates

United Kingdom

Study participating centre
GlaxoSmithKline
Greenford, Middlesex
United Kingdom
UB6 OHE

Germany

Greece

Iran

**Organisation**GlaxoSmithKline

Sponsor information

### Sponsor details

Greenford Road Greenford United Kingdom UB6 0HE

### Sponsor type

Not defined

### **ROR**

https://ror.org/01xsqw823

# Funder(s)

## Funder type

Industry

**Funder Name** 

GlaxoSmithKline (GSK)

Alternative Name(s)

GlaxoSmithKline plc., GSK plc., GSK

**Funding Body Type** 

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

**United Kingdom** 

# **Results and Publications**

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

**Study outputs** 

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/06/2005		Yes	No